Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

8.4K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.4K
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

11.3K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Tuning the size and defect chemistry of TiO<sub>2</sub><i>via</i> flash nanoprecipitation for enhanced photocatalytic antibacterial activity.

Nanoscale·2026
Same author

Hydrogen-Bond-Assisted Hydroxylation of <i>o</i>-Fluorobenzamides: A Transition-Metal-Free Approach to Salicylamides.

Molecules (Basel, Switzerland)·2026
Same author

Reversible Tuning of Magnetic Order and Intrinsic Superconductivity in Strained FeTe Films via Stoichiometry Control.

ACS nano·2026
Same author

Inhibition of Histone Lactylation by Dichloromethane Extract From Patrinia scabiosaefolia Fisch on Acute Myeloid Leukemia Cells.

Chemistry & biodiversity·2026
Same author

[Chinese medicine Gandouling attenuates brain injury in hepatolenticular degeneration mice by inhibiting ferroptosis via the SIRT1/FoxO3 signaling pathway].

Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences·2026
Same author

Targeting dormant cancer cells: ferroptosis as a precision therapeutic strategy.

Cellular & molecular biology letters·2026

相关实验视频

Updated: May 12, 2025

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.1K

长非编码TP73-AS1:癌症中的潜在生物标志物和治疗标

Kejing Li1,2, Dapeng Zhao2,3,4, Xuena Liu2,3,4

  • 1School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China.

International journal of molecular sciences
|May 7, 2025
PubMed
概括

瘤蛋白73反感RNA1 (TP73-AS1) 是一种长长的非编码RNA,与癌症发展和耐药性有关. 它的调控机制和临床潜力作为生物标志物和治疗标被审查.

关键词:
TP73-AS1 这是一本书.生物标志物生物标志物癌症 癌症 癌症 癌症 癌症长非编码RNA是什么意思分子机制的分子机制.

更多相关视频

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

1.4K
Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

9.8K

相关实验视频

Last Updated: May 12, 2025

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.1K
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

1.4K
Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

9.8K

科学领域:

  • * 分子瘤学 * 分子瘤学
  • * 癌症基因组学 癌症基因组学
  • *RNA生物学 *RNA生物学

背景情况:

  • *瘤蛋白73反感RNA1 (TP73-AS1) 是一个长的非编码RNA (lncRNA),在各种癌症中表达失调.
  • *异常TP73-AS1表达与癌症发生,耐药性和患者预后相关.
  • *了解TP73-AS1的调节作用为癌症诊断和治疗提供了新的途径.

研究的目的:

  • *审查TP73-AS1在癌症中的分子结构和双重调控功能.
  • *阐明TP73-AS1影响癌症进展的分子机制.
  • * 突出TP73-AS1在瘤学的临床意义和治疗潜力.

主要方法:

  • *关于TP73-AS1在癌症中的现有研究的文献综述.
  • *分析TP73-AS1的分子相互作用,包括蛋白质结合和信号通路调节.
  • * 检查TP73-AS1作为微RNA的分子海绵的作用.
  • *汇编了TP73-AS1在胃癌,肺癌和结直肠癌等特定癌症中的参与数据.

主要成果:

  • *TP73-AS1在癌症中表现出多种分子机制,包括蛋白质结合,信号通路调节和作为分子海绵的作用.
  • *TP73-AS1在常见恶性瘤 (如胃癌 (GC),肺癌和结直肠癌 (CRC) 的发病过程中发挥着重要作用.
  • *TP73-AS1中的单核酸多态 (SNP) 与GC和CRC的风险增加有关.

结论:

  • *TP73-AS1是癌症发育和通过多个分子途径的进展的关键参与者.
  • *TP73-AS1显示出作为诊断生物标志物和各种癌症的治疗点的巨大潜力.
  • *进一步研究TP73-AS1的功能可能会导致癌症管理的新型临床策略.